MergerJul 27, 2026, 06:11 AM
Forte Biosciences to be Acquired by argenx for $2.2B, $77/Share
AI Summary
argenx BV will acquire Forte Biosciences for $77.00 per share in cash, totaling approximately $2.2 billion in equity value. The transaction, unanimously recommended by Forte Biosciences' board, involves a tender offer followed by a merger. This acquisition strengthens argenx's immunology pipeline with FB102, a first-in-class anti-CD122 antibody with clinical proof-of-concept in vitiligo and celiac disease. The deal represents an 86% premium to Forte Biosciences' recent volume-weighted average price and is expected to close in Q3 2026.
Key Highlights
- argenx to acquire Forte Biosciences for $77.00 per share in cash.
- Total equity value of the acquisition is approximately $2.2 billion.
- The offer price represents an 86% premium to Forte Biosciences' recent VWAP.
- Forte Biosciences' board unanimously recommended the offer to stockholders.
- Acquisition includes FB102, an anti-CD122 antibody with Phase 1b data in vitiligo and celiac disease.
- Transaction structured as a tender offer followed by a subsequent merger.
- The acquisition is expected to close in Q3 2026.
Price Impact
More from FBRX